潜江永安药业股份有限公司2025年第三季度报告

Core Viewpoint - The company has disclosed its third-quarter financial report, confirming the accuracy and completeness of the information provided, and has made significant changes in its corporate structure and management [2][12]. Financial Data - The third-quarter financial report has not been audited [11]. - The company reported no need for retrospective adjustments or restatements of previous accounting data [3]. - There are no non-recurring profit and loss items applicable for the reporting period [3]. Shareholder Information - As of the reporting period, the company holds 5,537,350 shares in its repurchase account, accounting for 1.88% of the total shares, ranking fourth among all shareholders [5]. - The top ten shareholders and their shareholding status have not changed due to any lending or borrowing activities [5]. Corporate Governance Changes - The company has amended its business scope and increased the number of board members from six to seven, adding one employee representative director and one vice chairman [6]. - The supervisory board has been abolished, with its functions transferred to the audit committee of the board [6]. Acquisition and Investment - The company has acquired 49.20% of the shares from minority shareholders of Hubei Ling'an Technology Co., Ltd. for 27 million yuan, resulting in full ownership of the subsidiary [6][7]. Management Changes - The company has elected Chen Zidi as the vice chairman and appointed several new senior management personnel, including Dong Shihao as vice general manager [13]. Legal Matters - The company is involved in a patent infringement lawsuit in the U.S. but received a favorable ruling, with the plaintiff required to compensate for some legal fees [9].